Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Goodwin Biotechnology, Aspyrian Therapeutics Collaborate on Innovative Antibody Drug Conjugate

Published: Tuesday, March 25, 2014
Last Updated: Wednesday, March 26, 2014
Bookmark and Share
The agreement is for the technology transfer, process development, scale - up, and cGMP manufacturing of a novel Antibody Drug Conjugate (ADC) for use in Phase I clinical trials.

Goodwin Biotechnology, Inc. announced the agreement with Aspyrian Therapeutics, Inc. for use in Phase I clinical trials
.
Aspyrian Therapeutics has secured an exclusive license from the National Cancer Institute for a new ADC technology platform, Near ‐ infrared Photoimmunotherapy (PIT), which permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor. Because the payload in this unique ADC is inert until it is both in the tumor and activated by near ‐ infrared (NIR) light, it overcomes the dose ‐ limiting adverse effects that have hindered the development of conventional, toxin ‐ loaded ADC systems.

“We are pleased to have been selected to partner with Aspyrian Therapeutics for this leading edge ADC project,” said SooYoung Lee, PhD, Chief Operating Officer at Goodwin Biotechnology. “This important project is a testament to our experience and expertise in bioconjugation that has been developed and refined over more than a decade. This initiative has been led by Muctarr Sesay, PhD, Vice President of Process Development who is one of the pioneers in process development and cGMP manufacturing of many ADCs and biologic drug conjugates, which Goodwin has successfully manufactured for human clinical studies.”

“The technical expertise that Goodwin Biotechnology offers in the field of bioconjugation, coupled with the responsiveness and flexibility they exhibited during the selection process, made them the obvious choice,” noted Miguel Garcia ‐ Guzman, PhD, Chief Scientific Officer at Aspyrian Therapeutics. “Our mission is to leverage the potential of the PIT platform by developing a pipeline of proprietary and partnered ADC products, and this collaboration represents a critical milestone in this endeavor.”
Near ‐ infrared Photoimmunotherapy (PIT) is based on three components: 1. An antibody that binds to cell ‐ surface antigens. 2. The NIR IR700DX dye conjugated to the antibody via a stable linkage. 3. NIR light dosimetry to activate the conjugate (cell killing occurs whether the conjugate is surface ‐ bound or internalized).

Upon administration of non ‐ ionizing NIR light, PIT induces rapid cell killing by localized disruption of cell membranes of only those cells targeted by the antibody conjugate. Importantly, unbound conjugates and free dye do not elicit any phototoxicity upon NIR irradiation. The combination of selective binding to surface antigens and organ ‐ localized NIR activation permits highly efficacious disease ‐ specific ablation, while sparing nearby healthy tissues and structures. 
                  


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Goodwin Biotechnology and Aspyrian Therapeutics Collaborate
Collaboration on the successful GMP manufacturing and IND submission for a novel Antibody Drug Conjugate platform.
Friday, June 12, 2015
GBI and Coldstream Laboratories Announce a Collaboration
Collaboration to develop and manufacture cytotoxic Antibody Drug Conjugates.
Tuesday, May 07, 2013
Scientific News
'Crumpled' Filter to Slash Energy Consumption
Scientists have developed an ultra-thin, super-strong membrane to filter liquids and gases, with the potential to cut energy consumption in industry.
Tackling Chemical Safety Rules and Regulations
Helsinki Chemicals Forum continues to lead international chemicals safety and management discussions.
Pioneering New Method to Map Enzyme Activity
Cardiff University researchers new discovery could have wide-reaching implications for the creation of manufactured goods, biofuels and therapeutic drugs.
Euro Vision turns Reality for Australia’s Iconic ‘Green Whistle’
Patients will soon benefit from a unique invention, with emergency pain killer Penthrox receiving initial regulatory approval for sale in the European and UK markets.
Gaining the Full Benefit of Microflow Electrolysis Cells
This paper sets out the factors that should be considered in seeking good performance from microflow cells for organic electrosynthesis.
Are Chemical Safety Regulations Changing Your Laboratory?
GHS changes to country chemical regulations affect everyone.
Continuous Flow of Breakthroughs for Vapourtec
Flow chemistry systems designed and manufactured by Vapourtec have recently reached the milestone of having been cited in 150 peer review publications.
A Continuous Flow System for the Measurement of Ambient Nitrogen Oxides
The proposed method can be used in industrial locations to continuously monitor ambient NOx levels and it can be automated for measuring the variation of NOx concentrations.
Accelerating Spirocyclic Polyketide Synthesis
Powerful flow chemistry techniques used for complex multi-stage synthesis of spirocyclic polyketides.
Syrris Atlas has the Midas Touch with Nanoparticles
Spanish biotechnology company Midatech Biogune is taking advantage of our Atlas Potassium reactor systems to produce custom-made functionalized gold nanoparticles for medicinal use.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!